bind to G protein-coupled formyl peptide receptors (Fpr) and activate diverse cellular 23 signaling pathways. ANXA1 is known to be expressed in cells of the juxtaglomerular 24 apparatus, but its relation to the expression of cyclooxygenase 2 (COX-2) in thick 25 ascending limb and macula densa cells has not been elucidated. We hypothesized that 26 ANXA1 regulates the biosynthesis of COX-2. ANXA1 abundance in rat kidney macula 27 densa was extensively co-localized with COX-2 (95%). Furosemide, an established 28 stimulus for COX-2 induction, caused enhanced expression of both ANXA1 and COX-2 29 with maintained co-localization (99%). In ANXA1-deficient mice, COX-2-positive cells 30 were more numerous than in control mice (+107%; normalized to glomerular number; 31 p<0.05) and renin expression was increased (+566%; normalized to glomerular number; dietary salt intake, and NaCl transport blockade by furosemide (17, 40, 46) . Conversely, 57 high salt intake, high circulating levels of angiotensin (Ang) II, and increased renal 58 perfusion pressure reduce COX-2 abundance (16, 40) . Glucocorticoids and 59 mineralocorticoids also effectively inhibit 48) . To date, the mechanisms 60 involved in the control of juxtaglomerular COX-2 synthesis are imperfectly defined. 61 Previous experimental evidence indicates that intrinsic proteins participate in the 62 regulation of prostaglandin synthesis during inflammation. Of particular interest in this 63 regard is annexin A1 (ANXA1), a calcium-dependent phospholipid-binding protein that 64 mediates glucocorticoid action, reduces cytosolic phospholipase A2 by reducing PLA2 65 gene expression, and limits COX-2 abundance (11, 20, 31) . ANXA1 is secreted in 66 response to glucocorticoids in a cell-specific process involving its phosphorylation and 67 excretion by the ATP-binding cassette transporter ABCA1 (10, 38, 44 was verified by conventional PCR using specific primers (table 1). All DNA primers were 176 designed using NCBI primer blast software (NCBI, Bethesda, USA). Total mRNA was 177 isolated using the Qiagen RNeasy mini kit following the manufacturer's protocol (Qiagen, 178 Hilden, Germany). After digestion of genomic DNA by DNase 1 treatment (Qiagen, 179 Hilden, Germany) cDNA was generated by reverse transcription using the Applied distributed throughout the cytosol and less intense in the nucleus (Fig. 1A) . This 256 intracellular distribution pattern is recapitulated in MMDD1 cells (Fig. 1B) .
257
Analysis of the intracellular COX-2 (Fig. 1 C,D) and PLA2G4 (Fig. 1E,F) 258 distribution demonstrated a cytosolic pattern with an accumulation of immunoreactive 259 protein in the perinuclear space of rat macula densa (Fig. 1C,E ) and MMDD1 cells (Fig. 260 1D,F), thus confirming previous data (17, 28).
262
MMDD1 mRNA expression profile.
263
In situ hybridization for ANXA1 confirmed accumulation of ANXA1 mRNA in the 264 macula densa of control rats ( Fig. 2A) . PCR analysis revealed the presence of mRNA for 265 ANXA1, COX-2 and the ANXA1 receptors Fpr1, Fpr2 and Fpr3 in both murine kidney 266 and MMDD1 cells (Fig. 2B ). In addition, we also detected mRNA for the putative ANXA1 Effect of furosemide treatment on macula densa ANXA1 expression.
271
The effect of macula densa salt reabsorption on ANXA1 expression was tested in 272 furosemide-treated rats. Treatment caused an increase in the number of cells with 273 strong ANXA1 immunoreactivity compared to control animals (Fig. 3A,B Virtually all NOS1 immunoreactive macula densa cells also expressed high levels of 281 ANXA1 both in controls and in furosemide-treated specimens alike (Fig. 4) . concomitant treatment with CsH, while CsH alone had no effect (Fig. 11) . Co-application 347 of Dex and WRW4 had no effect (data not shown). MMDD1 COX-2 expression. In contrast, the Fpr2/Fpr3 antagonist WRW4 had no effect. 
